Skip to main content

Table 1 Baseline characteristics of eligible clinical trials

From: Comparison of the Ahmed glaucoma valve with the Baerveldt glaucoma implant: a meta-analysis

Author (Year)

Design

Inclusion criteria

Number of eyes

Sex (M/F)

Age (year)

Models of AGV

Models of BGI

IOP (mmHg) Standards of Success

Follow-up duration (months)

Baseline IOP (mmHg)

Budenz DL (2015)

RCT

>18y

A:143

A:73/70

A:65.4 ± 12.8

FP7

350

5≤ IOP ≤21 and ≥20 % reduction

60

A:31.2 ± 11.2

B:133

B:70/63

B:62.2 ± 14.2

B:31.8 ± 12.5

Christakis PG (2013)

RCT

>18y

A:124

A:65/59

A:65 ± 17

FP7

350

5≤ IOP ≤21* and ≥20 % reduction

36

A:31.1 ± 10.5

B:114

B:41/73

B:67 ± 15

B:31.7 ± 11.1

El Gendy NM (2012)

Retro

<18y

A:11

A:4/7

A:6.7

S2

250

8≤ IOP ≤24

A:32.4

A:39.8 ± 6.2

B:20

B:12/8

B:5.4

B:45.6

B:33.8 ± 5.7

Goulet RJ (2008)

Retro

All ages

A:59

A:25/34

A:66.3 ± 15.14

S2

250

5< IOP <22 and ≥20 % reduction

A:20.0 ± 26.7

A:35.3 ± 13.4

B:133

B:64/69

B:64.3 ± 16.9

B:22.9 ± 19.9

B:35.3 ± 12.9

Tsai JC (2006)

Retro

>18y

A:48

A:18/30

A:69.2

S2

250 and 350

6≤ IOP ≤21 and ≥20 % reduction

48

A:38.5

B:70

B:36/34

B:62.3

B:34.6

Tesser R (2005)

Retro

<18y, concurrent primary or secondary IOL implantation

A:3

ND

7.6

S2

250 and 350

IOP ≤22

21

A:35 ± 4.6

B:6

B:31.3 ± 0.8

Chung AN (2004)

Retro

>18y,concurrent Phaco and IOL implant

A:16

15/17

58 ± 16

ND

350

6≤ IOP ≤21

13 ± 5

A:26.2 ± 13.4

B:16

B:29.7 ± 13.4

Syed HM (2004)

Case control

All ages, Baerveldt implantation were matched case by case with Ahmed valve implantation

A:32

A:20/12

A:58 ± 24

Polypropylene

350

5< IOP <22 and ≥30 % reduction

8–16

A:30.69 ± 10.28

B:32

B:13/19

B:61 ± 23

B:30.09 ± 9.17

Wang JC (2004)

Retro

All ages

A:18

A:10/8

A:60.0 ± 18.2

S2

250

IOP <22

A:22.2 ± 9.2

A:43.7 ± 9.3

B:24

B:15/8

B:48.1 ± 23.2

B:22.8 ± 8.7

B:40.1 ± 13.8

Beck AD (2003)

Retro

<2y

A:32

ND

7mon ± 5.1

S2 and S3

250 and 350

IOP <23

A:33.0 ± 25.5

A:32.2 ± 7.0

B:14

B:24.9 ± 12.9

B:33.5 ± 5.6

  1. RCT: prospective randomized controlled trial; Retro: retrospective comparative controlled trial; ND: no details; IOL: Intraocular lens; Phaco: phacoemulsification; IOP: intra-ocular pressure; AGV (A): Ahmed glaucoma valve group; BGI (B): Baerveldt Glaucoma Implant group
  2. *The study reported set several different IOP criteria (14 mmHg, 18 mmHg, and 21 mmHg). We adopted the criterion of 21 mmHg